Editorials

Profits, Pressure, and Perception: Expensive Research Collides with Medicine
J. Hoey .................................................. 1661

Exclusivity versus the Hierarchy, or Fear and Loathing of the Undefined
R.E. Petty .................................................. 1663

Comment: Fibromyalgia — Real or Imagined?
D.A. Gordon ............................................. 1665

Pain is Real; Fibromyalgia Isn’t
G.E. Ehrlich .................................................. 1666

“Fibromyalgia” and the Medicalization of Misery
N.M. Hadler .................................................. 1668

Stop Using the American College of Rheumatology Criteria in the Clinic
F. Wolfe .................................................. 1671

Articles

Search for Correlation of CD8 T Cell Response to Epstein-Barr Virus with Clinical Status in RA: A 15 Month Followup Pilot Study
J-M. Berthelot, X. Saulquin, M. Coste-Burel, et al . . 1673

Preferential Induction of Prodestructive MMP-1 and Proinflammatory IL-6 and PGE2 in RA Synovial Fibroblasts via TNF Receptor 55
S. Alsalameh, R.J. Amin, E. Kunisch, H.E. Jasin, R.W. Kinne .................................................. 1680

The Predictive Value of Anti-Cyclic Citrullinated Peptide Antibodies in Early Arthritis
L.M.A. Jansen, D. van Schaardenburg, I.E. van der Horst-Bruinsma, R.J. van de Stadt, M.H.M.T. de Koning, B.A.C. Dijkmans .................................................. 1691

Recombinant Human Mab Specific for Citrulline-Containing Peptides from Phage Display Libraries Derived from Patients with RA

Differential Expression of Leukotriene B Receptor Subtypes (BLT1 and BLT2) in Human Synovial Tissues and SF Leukocytes of Patients with RA
A. Hashimoto, H. Endo, I. Hayashi, et al .................................................. 1712

Intraarticular Release and Accumulation of Defensins and Bactericidal/Permeability-Increasing Protein in Patients with RA
M.I. Bokarewa, T. Jin, A. Tarkowski .................................................. 1719

Toward a Definition and Method of Assessment of Treatment Failure and Treatment Effectiveness: The Case of Leflunomide versus Methotrexate
F. Wolfe, K. Michaud, B. Stephenson, J. Doyle .................................................. 1725

Description of Stable Pain in RA: A 6 Year Study
P.A. Roche, A.C. Kestov, H.M. Heim .................................................. 1733

Reading and Interpreting Economic Evaluations in RA: An Assessment of Selected Instruments for Critical Appraisal
M.H. Weisman, A.D. Gano Jr, S.E. Gabriel, et al .................................................. 1739

Evidence for Immunostimulatory Effects of IM Gold in Patients with RA: Correlation with Skin Reactions
S. Ernestam, J. Lamp, S. Rogberg, J. Rönnelid, L. Klareskog, I. Hafström .................................................. 1748

Adherence to Ophthalmologic Monitoring for Antimalarial Toxicity in a Lupus Cohort
S. Bernatsky, C. Pineau, L. Joseph, A. Clarke .................................................. 1756

Information on Diagnosis and Management of SLE Derived from the Routine Measurement of 8 Nuclear Autoantibodies
G.P. Ignat, A-C. Rat, J.J. Sychra, J. Vo, J. Varga, M. Teodorescu .................................................. 1761

Chemokine Receptor CCR2/CCR5 Polymorphism in Spanish Patients with SLE
F. Aguilar, A. Nuñez-Roldán, B. Torres, et al .................................................. 1770

IFN Plus Ribavirin in Patients with HCV Positive Mixed Cryoglobulinemia Resistant to IFN
C. Mazaro, F. Zorat, C. Comar, et al .................................................. 1775

Frequency and Analysis of Factors Closely Associated with the Development of Depressive Symptoms in Patients with Scleroderma
E. Matsuura, A. Ohta, F. Kanega, et al .................................................. 1782

A Systematic Review of the Outcomes of Digital Sympathectomy for Treatment of Chronic Digital Ischemia
S.V. Kotsis, K.C. Chung .................................................. 1788

Role of Immunosuppressive Therapy on Clinical, Immunological, and Angiographic Outcome in Active Takayasu’s Arteritis

Contents continued opposite inside back cover . .
Expression of Granzyme B in Human Articular Chondrocytes
K. Horiuchi, S. Saito, R. Sasaki, T. Tomatsu, Y. Toyama

In Situ Immunophenotype of the Inflammatory Infiltrate in Eosinophilic Fasciitis
C. Toquet, M.A. Hamidou, K. Renaudin, et al

AS in Shantou, China: 15 Years’ Clinical Experience
Q.Y. Zeng

The Risk of Contralateral Total Knee Arthroplasty After Knee Replacement for OA
M. McMahon, J.A. Block

Avocado/Soybean Unsaponifiables Increase Aggrecan Synthesis and Reduce Catabolic and Proinflammatory Mediator Production by Human Osteoarthritic Chondrocytes
Y.E. Henrotin, C. Sanchez, M.A. Deberg, et al

FM in an Amish Community: A Controlled Study to Determine Disease and Symptom Prevalence
K.P. White, J. Thompson

Oral Symptoms Associated with FM
N.L. Rhodus, J. Fricton, P. Carlson, R. Messner

Patient and Provider Factors Related to Comprehensive Arthritis Care in a Community Setting in Ontario, Canada

The Dunlop-Dottridge Lecture: Medical Publication Ethics
D.A. Gordon

Pediatric Rheumatology
Classification of JIA: Should Family History Be Included in the Criteria? P. Manners, J. Lesslie, D. Speidelwilde, D. Tunbridge

Case Reports
Etanercept Ameliorates Sarcoidosis Arthritis and Skin Disease D. Khanna, M.R. Liebling, J.S. Louie

Intraarticular Tophi in a Joint Without a Previous Gouty Attack K-H. Yu

Images in Rheumatology
IV Cyclophosphamide and High Dose Corticosteroids Improve MRI Lesions in Demyelinating Syndrome in SLE F.K. Leung, P.R. Fortin

Canadian Rheumatology Association Meeting
Mont Tremblant, Canada
February 26 – March 1, 2003
Introduction
Podium Presentations
Posters

Correspondence
The Approaching Crisis in Rheumatologic Care
A.J. Morris

Reply J. Lewtas

MTX, HCQ, and Intramuscular Gold in RA
S. Wassenberg, R. Rau

Reply D. Albert, F. Wolfe, J. Fries

Letter
MRI Criteria to Differentiate Inclusion Body Myositis from Polymyositis G.J.D. Hengstman

Notices
Online Instructions